Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Biotechnology

Healthcare
$29.68 +1.50%

+$0.50 today

Market cap
$1.78B
Beta
0.59
P/E (TTM)
-4.7
EPS (TTM)
-$7.19
52W Low $22.24High $46.00

Volume 0.60M

Average 1.11M

AGIO Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Agios Pharmaceuticals, Inc.NASDAQ: AGIO

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 87.1%

Gross margin was 87.1% in Q1 FY2026, up 14.2 pp from a year earlier. On a trailing-twelve-month basis it was 82.1%, up 2.3 pp year over year. Over 3 fiscal years it narrowed by 9.4 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
87.1%+2.8 pp QoQ
Last fiscal yearDec 2025
78.7%-9.9 pp YoY
LTMMar 2026
82.1%+2.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+14.2 pp——
1 year-9.9 pp——
3 years-9.4 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
78.7%
Year-over-year change
-9.9pp

Gross Margin vs competitors

How AGIO compares with its peers on the latest reported figures

  • AGIO's LTM Mar 2026 gross margin of 82.1% is the 4th highest of the 6 companies compared; the peer median is 82.1%.
  • Its year-over-year change of +2.3 pp is the 2nd highest of 6, against a peer median of -1.7 pp.
  • Over three fiscal years its change of -9.4 pp compares with a peer median of -3.2 pp.
AGIO Competitors Peer median
Gross Margin for AGIO and competitors
Company Period LTM level YoY 3-year change
PHARPharming Group N.V.LTM Mar 202687.3% -1.7 pp-3.6 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202683.6% -1.6 pp-8.4 pp
PTCTPTC Therapeutics, Inc.LTM Jun 202682.1% -14.9 pp+2.2 pp
AGIOAgios Pharmaceuticals, Inc.LTM Mar 202682.1% +2.3 pp-9.4 pp
MIRMMirum Pharmaceuticals, Inc.LTM Jun 202681.7% +2.7 pp-3.2 pp
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 202623.5% -73.5 pp+0.3 pp
IRONDisc Medicine, Inc.FY2025— ——
Peer median (excluding AGIO) 82.1%-1.7 pp-3.2 pp

Competitors are the stored peer set for AGIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue014.24M26.82M36.5M54.03M
Cost of Revenue18.78M1.7M9.5M4.17M11.52M
Gross Profit(18.78M)12.54M17.32M32.33M42.51M
Gross Margin—88.0%64.6%88.6%78.7%
Research & Development256.97M279.91M288.9M301.29M334.36M
Selling, General & Admin121.45M121.67M119.9M156.78M180.28M
Operating Expenses359.64M401.58M408.81M458.07M514.64M
Depreciation & Amortization18.78M8.56M6.62M5.65M5.18M
EBITDA(337.73M)(223.24M)(345.47M)723.62M(408.62M)
EBITDA Margin—-1567.7%-1287.9%1982.6%-756.3%
Operating Income(378.42M)(389.05M)(391.49M)(425.74M)(472.13M)
Operating Margin—-2732.1%-1459.5%-1166.5%-873.9%
Interest Income836K12.79M33.34M48.08M56.38M
Interest Expense00000
Other Income / Expenses21.91M157.25M39.4M1.14B58.34M
Income Before Tax(356.51M)(231.8M)(352.09M)717.97M(413.8M)
Pre-Tax Margin—-1627.8%-1312.6%1967.1%-765.9%
Income Tax Expense00044.24M(1.02M)
Net Income1.6B(231.8M)(352.09M)673.73M(412.78M)
Net Margin—-1627.8%-1312.6%1845.9%-764.0%
EPS (Basic)(6.36)(4.23)(6.33)11.86(7.12)
EPS (Diluted)(6.36)(4.23)(6.33)11.64(7.12)
Weighted Avg Shares60.45M54.79M55.65M56.81M57.97M
Weighted Avg Shares (Diluted)60.45M54.79M55.65M57.89M57.97M

Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Intrinsic Alpha fair value

Locked

Current Price

$29.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.